公开(公告)号：US11279682B2

公开(公告)日：2022-03-22

申请号：US16294647

申请日：2019-03-06

Applicant: H. Lundbeck A/S

Inventor： Heidi Lopez de Diego ,  Kim Lasse Christensen ,  Rene Holm ,  Jens Kateb

IPC: C07D295/096 ,  C07D207/28

Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.

公开(公告)号：US20200163959A1

公开(公告)日：2020-05-28

申请号：US16502677

申请日：2019-07-03

Applicant: H. Lundbeck A/S

Inventor： André Faldt ,  Heidi Lopez de Diego ,  Rene Holm

IPC: A61K31/495 ,  A61K9/14 ,  C07D295/096

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

公开(公告)号：US20190167667A1

公开(公告)日：2019-06-06

申请号：US16020799

申请日：2018-06-27

Applicant: H. Lundbeck A/S

Inventor： Svend Treppendahl ,  Heidi Lopez de Diego

IPC: A61K31/495 ,  C07D295/096 ,  A61K9/08 ,  C07C59/08

Abstract: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.

公开(公告)号：US10034876B2

公开(公告)日：2018-07-31

申请号：US15271543

申请日：2016-09-21

Applicant: H. Lundbeck A/S

Inventor： Svend Treppendahl ,  Heidi Lopez de Diego

IPC: A61K31/495

CPC classification number: A61K31/495 ,  A61K9/08 ,  C07C59/08 ,  C07D295/096

Abstract: Liquid formulations of lactic acid addition salts of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine are provided.

公开(公告)号：US20180333408A1

公开(公告)日：2018-11-22

申请号：US15845677

申请日：2017-12-18

Applicant: H. Lundbeck A/S

Inventor： André Faldt ,  Heidi Lopez de Diego ,  Rene Holm

IPC: A61K31/495 ,  C07D295/096 ,  A61K9/14

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

公开(公告)号：US09227946B2

公开(公告)日：2016-01-05

申请号：US14242337

申请日：2014-04-01

Applicant: H. Lundbeck A/S

Inventor： Andre Faldt ,  Rene Holm ,  Heidi Lopez de Diego

IPC: A61K31/495 ,  C07D295/096 ,  A61K9/14

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Abstract translation: 1- [2-（2,4-二甲基苯基硫烷基）苯基]哌嗪显示出对SERT，5-HT3和5-HT1A的有效活性，并且可以用于治疗认知障碍，特别是抑郁症患者。

公开(公告)号：US11858954B2

公开(公告)日：2024-01-02

申请号：US17392970

申请日：2021-08-03

Applicant: H. Lundbeck A/S

Inventor： Klaus Gjervig Jensen ,  Lisbet Kværnø ,  Morten Jørgensen ,  Martin Juhl ,  Heidi Lopez de Diego ,  Karin Fredholt ,  Frans Dennis Therkelsen ,  Tobias Gylling Frihed ,  Mikkel Fog Jacobsen

IPC: C07H15/26

CPC classification number: C07H15/26 ,  C07B2200/13

Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below.




The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.

公开(公告)号：US10287261B2

公开(公告)日：2019-05-14

申请号：US15152902

申请日：2016-05-12

Applicant: H. Lundbeck A/S

Inventor： Heidi Lopez de Diego ,  Kim Lasse Christensen ,  Rene Holm ,  Jens Kateb

IPC: C07D295/096 ,  A61P25/00 ,  A61K31/495 ,  C07D207/28

Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.

公开(公告)号：US09125909B2

公开(公告)日：2015-09-08

申请号：US14326725

申请日：2014-07-09

Applicant: H. Lundbeck A/S

Inventor： Benny Bang-Andersen ,  Andre Faldt ,  Arne Mork ,  Heidi Lopez de Diego ,  Rene Holm ,  Tine Bryan Stensbol

IPC: A61K31/495 ,  C07D295/096

CPC classification number: A61K31/495 ,  A61K9/14 ,  C07D295/096 ,  Y10T428/2982

Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.

Abstract translation: 本公开涉及结晶形式的1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪或其药学上可接受的盐。

公开(公告)号：US20230021520A1

公开(公告)日：2023-01-26

申请号：US17949188

申请日：2022-09-20

Applicant: H. Lundbeck A/S

Inventor： André Faldt ,  Heidi Lopez de Diego ,  Rene Holm ,  Michael J. Mealy

IPC: A61K31/495 ,  C07D295/096 ,  A61K9/14

Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.